source
- Inhibrx says combo therapy shrank more tumors than Merck's Keytruda aloneSan Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more t…Endpoints · 3mo ago↗ source
- Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialInhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.BioPharma Dive · 3mo ago↗ source
- Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBraveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…